AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7672877 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac SR 600 mg u.i.d. for 8 weeks
Number of subjects: 120
Study 7672877 — intervention group
Group type: COMPARATOR
Intervention: Tenoxicam 20 mg u.i.d. for 8 weeks
Number of subjects: 120
Study 2609944 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine acetate in periodontal dressing
Number of subjects: 11
Study 2609944 — intervention group
Group type: COMPARATOR
Intervention: Control dressings (without chlorhexidine)
Number of subjects: 11
Study 31969175 — intervention group
Group type: EXPERIMENTAL
Intervention: Active de-implementation strategy for reducing low-value pharmacological prescribing of statins
Number of subjects: 0
Study 31969175 — intervention group
Group type: COMPARATOR
Intervention: Usual procedures for dissemination of clinical practice guidelines (control)
Number of subjects: 0
Study 31092043 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) with dual-site stimulation over the auditory temporal and frontal regions (TF group)
Number of subjects: 0
Study 31092043 — intervention group
Group type: COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS) with single-site stimulation over the auditory temporal cortex (T group)
Number of subjects: 0
Study 31092043 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (S group)
Number of subjects: 0
Study 27260764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise program (n=27)
Number of subjects: 54
Study 27260764 — intervention group
Group type: COMPARATOR
Intervention: Control group (leaflet information, n=27)
Number of subjects: 54
Study 26567256 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed shared decision-making programme (ISDM-P)
Number of subjects: 154
Study 26567256 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (sham)
Number of subjects: 154
Study 23652896 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antioxidant complex containing vitamins C and E and ferulic acid
Number of subjects: 12
Study 23652896 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 12
Study 23652896 — intervention group
Group type: COMPARATOR
Intervention: Untreated site (positive control)
Number of subjects: 12
Study 23652896 — intervention group
Group type: COMPARATOR
Intervention: Negative control (no treatment)
Number of subjects: 12
Study 20175775 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 26
Study 20175775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 18619791 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 100
Study 18619791 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic treatment
Number of subjects: 100
Study 15935538 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 128
Study 15935538 — intervention group
Group type: COMPARATOR
Intervention: Females
Number of subjects: 128
Study 12814453 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafcillin 500 mg four times daily for 5 days
Number of subjects: 9
Study 12814453 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 10 mg
Number of subjects: 9
Study 12814453 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafcillin pretreatment
Number of subjects: 9
Study 12814453 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 9
Study 10996104 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical valves
Number of subjects: 1229
Study 10996104 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioprosthesis
Number of subjects: 1229
Study 10996104 — intervention group
Group type: COMPARATOR
Intervention: Valve type (Mechanical vs Bioprosthesis)
Number of subjects: 1229
Study 8795732 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (1,000 mg)
Number of subjects: 12
Study 8795732 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 (6% CO2, 94% O2)
Number of subjects: 12
Study 8795732 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide + CO2
Number of subjects: 12
Study 8795732 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide
Number of subjects: 12
Study 8795732 — intervention group
Group type: COMPARATOR
Intervention: CO2
Number of subjects: 12
Study 8320924 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophane membrane hemodialysis
Number of subjects: 10
Study 8320924 — intervention group
Group type: EXPERIMENTAL
Intervention: AN69 membrane hemodialysis
Number of subjects: 10
Study 8320924 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 10
Study 3711365 — intervention group
Group type: EXPERIMENTAL
Intervention: lithium + sulindac (300 mg/day)
Number of subjects: 13
Study 3711365 — intervention group
Group type: EXPERIMENTAL
Intervention: lithium + naproxen (750 mg/day)
Number of subjects: 13
Study 3711365 — intervention group
Group type: COMPARATOR
Intervention: lithium alone
Number of subjects: 13
Study 30541220 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 60
Study 25831599 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating-rotating power toothbrush with angled CrissCross bristles (Oral-B Pro 7000 SmartSeries and Oral-B CrossAction brush head)
Number of subjects: 130
Study 25831599 — intervention group
Group type: COMPARATOR
Intervention: Marketed sonic toothbrush (Colgate ProClinical A1500 with the Triple Clean brush head)
Number of subjects: 130
Study 22738715 — intervention group
Group type: EXPERIMENTAL
Intervention: Web CBT plus weekly telephone tracking
Number of subjects: 155
Study 22738715 — intervention group
Group type: EXPERIMENTAL
Intervention: Web CBT only
Number of subjects: 155
Study 22738715 — intervention group
Group type: COMPARATOR
Intervention: Weekly telephone tracking only
Number of subjects: 155
Study 22738715 — intervention group
Group type: COMPARATOR
Intervention: Neither Web CBT nor telephone tracking
Number of subjects: 155
Study 22738715 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-only condition
Number of subjects: 155
Study 22738715 — intervention group
Group type: EXPERIMENTAL
Intervention: Web plus tracking conditions
Number of subjects: 155
Study 22738715 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-only and Web plus tracking conditions
Number of subjects: 155
Study 19799592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2% (DT) added to timolol 0.5%
Number of subjects: 161
Study 19799592 — intervention group
Group type: COMPARATOR
Intervention: Brinzolamide 1% (BT) added to timolol 0.5%
Number of subjects: 161
Study 18613992 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative treatment group (lifestyle changes, red yeast rice, and fish oil)
Number of subjects: 74
Study 18613992 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (40 mg/d)
Number of subjects: 74
Study 16150503 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (RT)
Number of subjects: 1538
Study 16150503 — intervention group
Group type: EXPERIMENTAL
Intervention: Megavoltage RT
Number of subjects: 1538
Study 11927123 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin)
Number of subjects: 101
Study 11927123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 10713867 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (group R)
Number of subjects: 45
Study 10713867 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 45
Study 10713867 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Remifentanil and Propofol (group RP)
Number of subjects: 45
Study 7604788 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 57
Study 2379228 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg orally thrice daily for seven days
Number of subjects: 61
Study 2379228 — intervention group
Group type: COMPARATOR
Intervention: Cloxacillin 500 mg orally thrice daily for seven days
Number of subjects: 61
Study 102115 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorimipramine 25 mg t.i.d.
Number of subjects: 6
Study 102115 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline 25 mg t.i.d.
Number of subjects: 6
Study 102115 — intervention group
Group type: COMPARATOR
Intervention: TRH 200 microgram i.v. stimulation
Number of subjects: 6
Study 30316719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalad‐caudad blunt expansion of uterine incision
Number of subjects: 839
Study 30316719 — intervention group
Group type: COMPARATOR
Intervention: Transverse (lateral‐lateral) expansion
Number of subjects: 839
Study 28639533 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (group R, n = 15)
Number of subjects: 45
Study 28639533 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (group N, n = 15)
Number of subjects: 45
Study 28639533 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil plus Nicardipine (group RN, n = 15)
Number of subjects: 45
Study 28639533 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine (group N)
Number of subjects: 45
Study 28639533 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil plus Nicardipine (group RN)
Number of subjects: 45
Study 25833714 — intervention group
Group type: COMPARATOR
Intervention: Task-sharing interventions delivered by trained and supervised non-specialist primary health care workers
Number of subjects: 0
Study 25833714 — intervention group
Group type: COMPARATOR
Intervention: Task-sharing counselling intervention for maternal depression delivered by non-specialist community health workers
Number of subjects: 0
Study 24498516 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (NS)
Number of subjects: 78
Study 24498516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (NS)
Number of subjects: 78
Study 21816478 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel resinate (75 mg) + aspirin (100 mg)
Number of subjects: 314
Study 21816478 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel bisulfate (75 mg) + aspirin (100 mg)
Number of subjects: 314
Study 21816478 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel resinate placebo + aspirin (100 mg)
Number of subjects: 314
Study 19030021 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg 6-month depot of leuprorelin acetate
Number of subjects: 0
Study 19030021 — intervention group
Group type: COMPARATOR
Intervention: 11.25 mg 3-month depot of leuprorelin acetate
Number of subjects: 0
Study 17075347 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine
Number of subjects: 60
Study 17075347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15331548 — intervention group
Group type: EXPERIMENTAL
Intervention: LoBAG diet (high-protein, low-carbohydrate diet)
Number of subjects: 8
Study 15331548 — intervention group
Group type: COMPARATOR
Intervention: Control diet (carbohydrate:protein:fat ratio of 55:15:30)
Number of subjects: 8
Study 15331548 — intervention group
Group type: EXPERIMENTAL
Intervention: LoBAG diet
Number of subjects: 8
Study 15331548 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 8
Study 11108568 — intervention group
Group type: EXPERIMENTAL
Intervention: Periurethral transurethral microwave thermotherapy (P-TUMT) using the TherMatrx TMx-2000 device
Number of subjects: 0
Study 11108568 — intervention group
Group type: COMPARATOR
Intervention: Conventional transurethral microwave thermotherapy (TUMT)
Number of subjects: 0
Study 9291903 — intervention group
Group type: COMPARATOR
Intervention: Single application of polidocanol 1%
Number of subjects: 854
Study 9291903 — intervention group
Group type: EXPERIMENTAL
Intervention: Single application of fibrin glue (FG)
Number of subjects: 854
Study 9291903 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily repeated application of fibrin glue (FG)
Number of subjects: 854
Study 8491905 — intervention group
Group type: EXPERIMENTAL
Intervention: FSE T2-weighted MRI
Number of subjects: 59
Study 8491905 — intervention group
Group type: COMPARATOR
Intervention: CSE T2-weighted MRI
Number of subjects: 59
Study 8491905 — intervention group
Group type: COMPARATOR
Intervention: CSE and FSE sequences
Number of subjects: 59
Study 3113913 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal glyceryl trinitrate (Suscard)
Number of subjects: 126
Study 3113913 — intervention group
Group type: COMPARATOR
Intervention: Sublingual glyceryl trinitrate (Nitromex)
Number of subjects: 126
Study 29925851 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS items (delusions, suspiciousness, hallucinations, anxiety, excitement, tension, conceptual disorganization)
Number of subjects: 267
Study 26661288 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5395
Study 26661288 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (enoxaparin followed by warfarin)
Number of subjects: 5395
Study 24717254 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg administered at 10:30 pm
Number of subjects: 12
Study 22381614 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Bond Plus (1-SEA) applied with phosphoric-acid etching to enamel
Number of subjects: 0
Study 22381614 — intervention group
Group type: COMPARATOR
Intervention: G-Bond Plus (1-SEA) applied without phosphoric-acid etching to enamel
Number of subjects: 0
Study 22381614 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Bond Plus (1-SEA) applied to dentine using self-etch protocol
Number of subjects: 0
Study 22381614 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Bond Plus (1-SEA) applied to dentine using dry-bonding etch-and-rinse protocol
Number of subjects: 0
Study 22381614 — intervention group
Group type: COMPARATOR
Intervention: G-Bond Plus (1-SEA) applied to dentine using wet-bonding etch-and-rinse protocol
Number of subjects: 0
Study 21246841 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion
Number of subjects: 36
Study 21246841 — intervention group
Group type: COMPARATOR
Intervention: Western medication (Seretide inhalant)
Number of subjects: 36
Study 18579976 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg intravenous HBB
Number of subjects: 104
Study 18579976 — intervention group
Group type: COMPARATOR
Intervention: 2 mL normal saline (Control)
Number of subjects: 104
Study 17213783 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 53
Study 17213783 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg
Number of subjects: 53
Study 12624556 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 1266
Study 11118471 — intervention group
Group type: EXPERIMENTAL
Intervention: RPR 109881A at 52.5 mg/m(2)
Number of subjects: 29
Study 11118471 — intervention group
Group type: EXPERIMENTAL
Intervention: RPR 109881A at 45 mg/m(2)
Number of subjects: 29
Study 11118471 — intervention group
Group type: EXPERIMENTAL
Intervention: RPR 109881A
Number of subjects: 29
Study 8886696 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 5 mg/day for 12 days during a 21-day cycle of transdermal estradiol (50 micrograms/day) for 6 cycles
Number of subjects: 28
Study 8886696 — intervention group
Group type: EXPERIMENTAL
Intervention: Medrogestone 5 mg/day for 12 days during a 21-day cycle of transdermal estradiol (50 micrograms/day) for 6 cycles
Number of subjects: 28
Study 2000785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase therapy
Number of subjects: 64
Study 6313523 — intervention group
Group type: EXPERIMENTAL
Intervention: C + H (Captopril 25 mg t.i.d. + Hydrochlorothiazide 15 mg t.i.d.)
Number of subjects: 625
Study 6313523 — intervention group
Group type: EXPERIMENTAL
Intervention: C + H (Captopril 25 mg b.i.d. + Hydrochlorothiazide 25 mg b.i.d.)
Number of subjects: 625
Study 6313523 — intervention group
Group type: EXPERIMENTAL
Intervention: C + H (Captopril 50 mg b.i.d. + Hydrochlorothiazide 25 mg b.i.d.)
Number of subjects: 625
Study 6313523 — intervention group
Group type: EXPERIMENTAL
Intervention: H (Hydrochlorothiazide 15 mg t.i.d.)
Number of subjects: 625
Study 6313523 — intervention group
Group type: COMPARATOR
Intervention: C (Captopril 25 mg t.i.d.)
Number of subjects: 625
Study 6313523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 625
Study 30958879 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity impairment improvement with acute-phase treatment in STAR∗D (F = 7.27; df = 2,2625; P <. 001)
Number of subjects: 2697
Study 30958879 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding activity impairment variables to depression severity measures
Number of subjects: 2697
Study 30958879 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR∗D trial model estimates
Number of subjects: 2697
Study 30055602 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 288
Study 30055602 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline injections
Number of subjects: 288
Study 27194304 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG+RES (282 mg EGCG and 80 mg RES per day)
Number of subjects: 38
Study 27194304 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG+RES
Number of subjects: 38
Study 27194304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 24287639 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic papillary balloon dilation (EPBD)
Number of subjects: 132
Study 24287639 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic biliary sphincterotomy (EBS)
Number of subjects: 132
Study 22801453 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 0
Study 22801453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 0
Study 22801453 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 19460913 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured care (n = 104)
Number of subjects: 205
Study 19460913 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients attaining >=3 treatment targets (n = 91)
Number of subjects: 205
Study 19460913 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 101)
Number of subjects: 205
Study 17396158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary soy protein
Number of subjects: 0
Study 15529620 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (dosage and duration not specified)
Number of subjects: 0
Study 15529620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11450676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone, 2 g daily for 30 days, followed by oral doxycycline, 200 mg daily for 60 days
Number of subjects: 129
Study 11450676 — intervention group
Group type: COMPARATOR
Intervention: Matching intravenous and oral placebos
Number of subjects: 129
Study 11450676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone and oral doxycycline
Number of subjects: 129
Study 10696354 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 7982727 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy for adhesiolysis
Number of subjects: 89
Study 7982727 — intervention group
Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 89
Study 7982727 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsies from adhesions and sactosalpinx
Number of subjects: 89
Study 3059456 — intervention group
Group type: EXPERIMENTAL
Intervention: Very detailed follow-up programme
Number of subjects: 600
Study 3059456 — intervention group
Group type: COMPARATOR
Intervention: Virtually no follow-up
Number of subjects: 600
Study 3059456 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated polypectomy
Number of subjects: 600
Study 29985281 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d) administered preoperatively for 5-7 days
Number of subjects: 70
Study 29985281 — intervention group
Group type: COMPARATOR
Intervention: Control treatment group
Number of subjects: 70
Study 29985281 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment group
Number of subjects: 70
Study 29985281 — intervention group
Group type: EXPERIMENTAL
Intervention: MiR-15a-5p mimic in cardiomyocytes
Number of subjects: 70
Study 27769054 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/cisplatin followed by surgery (CS)
Number of subjects: 281
Study 25620765 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral blockade with 0.5% bupivicaine before induction of general anesthesia
Number of subjects: 60
Study 25620765 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 60
Study 25620765 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral blockade with 0.5% bupivicaine
Number of subjects: 60
Study 25620765 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 25620765 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral blockade
Number of subjects: 60
Study 23433590 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (200 mg twice daily)
Number of subjects: 285
Study 23433590 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (600 mg once daily)
Number of subjects: 285
Study 20515559 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon Liquid (peppermint)
Number of subjects: 45
Study 20515559 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon Double Action Liquid (peppermint)
Number of subjects: 45
Study 20515559 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon Powder Formulation (fresh tropical)
Number of subjects: 45
Study 20515559 — intervention group
Group type: COMPARATOR
Intervention: Non-active sublingual control
Number of subjects: 45
Study 18455221 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose budesonide/formoterol (160/4.5 microg x 2 inhalations twice daily)
Number of subjects: 1225
Study 18455221 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable-dose budesonide/formoterol (adjustable from 2 inhalations [320/9 microg] twice daily to 2 inhalations [320/9 microg] once daily or 4 inhalations [640/18 microg] twice daily)
Number of subjects: 1225
Study 18455221 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose fluticasone propionate/salmeterol (250/50 microg x 1 inhalation twice daily)
Number of subjects: 1225
Study 17201838 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective HB pacing (SHBP)
Number of subjects: 17